Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Sofosbuvir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 839Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva Pharms' Generic Dextroamp Saccharate Receives Approval in the U.S.
    Teva Pharms' Generic Dextroamp Saccharate Receives Approval in the U.S.

    31 Jan 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210876

    FDA
    31 Jan 2022
    Share Share
    Teva Pharms' Generic Sofosbuvir Receives Approval in the U.S.
    Teva Pharms' Generic Sofosbuvir Receives Approval in the U.S.

    27 Jan 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211353

    FDA
    27 Jan 2022
    Share Share
    Malaysia set to become Hepatitis C treatment hub of Asia
    Malaysia set to become Hepatitis C treatment hub of Asia

    16 Nov 2021

    // BIOSPECTRUMASIA

    https://www.biospectrumasia.com/news/30/19355/malaysia-set-to-become-hepatitis-c-treatment-hub-of-asia.html

    BIOSPECTRUMASIA
    16 Nov 2021
    Share Share
    NPPA refuses Cipla’s application for discontinuation of four HIV drugs
    NPPA refuses Cipla’s application for discontinuation of four HIV drugs

    15 Sep 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=142519&sid=1

    PHARMABIZ
    15 Sep 2021
    Share Share
    FDA approves new formulation Gilead's Epclusa for Kids ages 3 and older with HCV
    FDA approves new formulation Gilead's Epclusa for Kids ages 3 and older with HCV

    10 Jun 2021

    // Jonathan.M SEEKING ALPHA

    https://seekingalpha.com/news/3705521-fda-approves-new-formulation-gileads-epclusa-for-children-ages-3-and-older-with-hcv

    Jonathan.M SEEKING ALPHA
    10 Jun 2021
    Share Share
    U.S. FDA Approves New Formulation of Epclusa
    U.S. FDA Approves New Formulation of Epclusa

    10 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210610005958/en

    BUSINESSWIRE
    10 Jun 2021
    Share Share